A Clinical trial to evaluate the pharmacokinetics, safety, efficacy and immunogenicity of Bmab-100 and Avastin in patients with metastatic colorectal cancer

Intervention1: Bmab-100: administered intravenously 7.5 mg/kg/body weight once every 3 weeks for 6 cycles.
Control Intervention1: Avastin (Roches bevacizumab): to administer 7.5mg/kg once evry 3 weeks for 6 cycles
Primary outcome(s): Single dose pharmacokinetic parameters for Bmab-100 and Avastin in terms of AUC0-t and Cmax [Cycle 1]Timepoint: Single dose pharmacokinetic parameters for Bmab-100 and Avastin in terms of AUC0-t and Cmax [Cycle 1]
Study Design: Randomized, Parallel Group Trial
Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded